{"id":696241,"date":"2024-04-24T12:18:02","date_gmt":"2024-04-24T12:18:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=696241"},"modified":"2024-04-24T12:18:02","modified_gmt":"2024-04-24T12:18:02","slug":"acute-gout-flare-market-to-register-incremental-growth-during-the-forecast-period-20232032-asserts-delveinsight-olatec-therapeutics-dyve-biosciences-changchun-genescience-pharma-regeneron","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acute-gout-flare-market-to-register-incremental-growth-during-the-forecast-period-20232032-asserts-delveinsight-olatec-therapeutics-dyve-biosciences-changchun-genescience-pharma-regeneron_696241.html","title":{"rendered":"Acute Gout Flare Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Olatec Therapeutics, Dyve Biosciences, Changchun GeneScience Pharma, Regeneron"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1713898830.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Acute Gout Flare Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Olatec Therapeutics, Dyve Biosciences, Changchun GeneScience Pharma, Regeneron\" src=\"https:\/\/www.abnewswire.com\/uploads\/1713898830.jpeg\" alt=\"Acute Gout Flare Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Olatec Therapeutics, Dyve Biosciences, Changchun GeneScience Pharma, Regeneron\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Acute Gout Flare Market Forecast report offers an in-depth understanding of the Acute Gout Flare, historical and forecasted epidemiology as well as the Acute Gout Flare market trends in the 7MM.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;Acute Gout Flare Market Insights, Epidemiology, and Market Forecast-2032&Prime;<\/strong> report offers an in-depth understanding of the Acute Gout Flare, historical and forecasted epidemiology as well as the Acute Gout Flare market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Acute Gout Flare market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-gout-flare-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Acute Gout Flare Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Acute Gout Flare Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The Acute Gout Flare market size is anticipated to grow with a significant CAGR during the study period (2019-2032)<\/p>\n<\/li>\n<li>\n<p>The overall occurrence of gout affects 1&ndash;4% of the general population. There is a higher susceptibility to gout in men compared to women. In Western countries, the prevalence is approximately 3&ndash;6% in men and 1&ndash;2% in women.<\/p>\n<\/li>\n<li>\n<p>Gout results in around 7 million outpatient visits in the United States each year, incurring a cost of almost USD 1 billion.<\/p>\n<\/li>\n<li>\n<p><strong>Key Acute Gout Flare Companies:<\/strong> Olatec Therapeutics, Dyve Biosciences, Changchun GeneScience Pharma, Regeneron Pharmaceuticals, Novartis, LG Chem, Novartis, Organon and Co, Revive Therapeutics, Ltd., and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Acute Gout Flare Therapies:<\/strong> Dapansutrile, DYV700, Genakumab for injection, Rilonacept, ACZ885, Tigulixostat, Canakinumab, MK0663, Bucillamine, and others<\/p>\n<\/li>\n<li>\n<p>The Acute Gout Flare epidemiology based on gender analyzed that Gout is three times more prevalent in males than females<\/p>\n<\/li>\n<li>\n<p>The Acute Gout Flare market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Gout Flare pipeline products will significantly revolutionize the Acute Gout Flare market dynamics.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acute Gout Flare Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">An acute gout flare refers to a sudden and intense episode of pain, swelling, redness, and tenderness in a joint caused by the inflammatory response to the crystallization of uric acid in the joint. Gout is a type of arthritis characterized by elevated levels of uric acid in the blood, leading to the formation of urate crystals in the joints.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Acute Gout Flare Market Forecast, Size &amp; Share Analysis Report:&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acute-gout-flare-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/acute-gout-flare-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Acute Gout Flare Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acute Gout Flare Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Acute Gout Flare market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Total Prevalence of Acute Gout Flare<\/p>\n<\/li>\n<li>\n<p>Prevalent Cases of Acute Gout Flare by severity<\/p>\n<\/li>\n<li>\n<p>Gender-specific Prevalence of Acute Gout Flare<\/p>\n<\/li>\n<li>\n<p>Diagnosed Cases of Episodic and Chronic Acute Gout Flare<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Acute Gout Flare epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-gout-flare-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Acute Gout Flare Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Acute Gout Flare Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Gout Flare market or expected to get launched during the study period. The analysis covers Acute Gout Flare market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Acute Gout Flare Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acute Gout Flare Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Dapansutrile:<\/strong> Olatec Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>DYV700:<\/strong> Dyve Biosciences<\/p>\n<\/li>\n<li>\n<p><strong>Genakumab for injection:<\/strong> Changchun GeneScience Pharma<\/p>\n<\/li>\n<li>\n<p><strong>Rilonacept:<\/strong> Regeneron Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p><strong>ACZ885:<\/strong> Novartis<\/p>\n<\/li>\n<li>\n<p><strong>Tigulixostat:<\/strong> LG Chem<\/p>\n<\/li>\n<li>\n<p><strong>Canakinumab:<\/strong> Novartis<\/p>\n<\/li>\n<li>\n<p><strong>MK0663:<\/strong> Organon and Co<\/p>\n<\/li>\n<li>\n<p><strong>Bucillamine:<\/strong> Revive Therapeutics, Ltd.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Acute Gout Flare market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-gout-flare-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Acute Gout Flare Treatment Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Acute Gout Flare Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Study Period: 2019&ndash;2032<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/p>\n<\/li>\n<li>\n<p><strong>Key Acute Gout Flare Companies:<\/strong> Olatec Therapeutics, Dyve Biosciences, Changchun GeneScience Pharma, Regeneron Pharmaceuticals, Novartis, LG Chem, Novartis, Organon and Co, Revive Therapeutics, Ltd., and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Acute Gout Flare Therapies:<\/strong> Dapansutrile, DYV700, Genakumab for injection, Rilonacept, ACZ885, Tigulixostat, Canakinumab, MK0663, Bucillamine, and others<\/p>\n<\/li>\n<li>\n<p><strong>Acute Gout Flare Therapeutic Assessment:<\/strong> Acute Gout Flare current marketed and Acute Gout Flare emerging therapies<\/p>\n<\/li>\n<li>\n<p><strong>Acute Gout Flare Market Dynamics:<\/strong> Acute Gout Flare market drivers and Acute Gout Flare market barriers&nbsp;<\/p>\n<\/li>\n<li>\n<p><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/p>\n<\/li>\n<li>\n<p><strong>Acute Gout Flare Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Acute Gout Flare Market Access and Reimbursement&nbsp;<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Acute Gout Flare companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-gout-flare-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Acute Gout Flare Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Acute Gout Flare Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Acute Gout Flare<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Acute Gout Flare<\/p>\n<p style=\"text-align: justify;\">4. Acute Gout Flare Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Acute Gout Flare Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Acute Gout Flare Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Acute Gout Flare Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Acute Gout Flare&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Acute Gout Flare Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Acute Gout Flare Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Acute Gout Flare Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Acute Gout Flare Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Acute Gout Flare Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Acute Gout Flare Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Acute Gout Flare Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Acute Gout Flare Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Acute Gout Flare Appendix<\/p>\n<p style=\"text-align: justify;\">18. Acute Gout Flare Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_72253.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=acute-gout-flare-market-to-register-incremental-growth-during-the-forecast-period-20232032-asserts-delveinsight-olatec-therapeutics-dyve-biosciences-changchun-genescience-pharma-regeneron\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=acute-gout-flare-market-to-register-incremental-growth-during-the-forecast-period-20232032-asserts-delveinsight-olatec-therapeutics-dyve-biosciences-changchun-genescience-pharma-regeneron\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Acute Gout Flare Market Forecast report offers an in-depth understanding of the Acute Gout Flare, historical and forecasted epidemiology as well as the Acute Gout Flare market trends in the 7MM. DelveInsight&rsquo;s &ldquo;Acute Gout Flare Market Insights, Epidemiology, and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/acute-gout-flare-market-to-register-incremental-growth-during-the-forecast-period-20232032-asserts-delveinsight-olatec-therapeutics-dyve-biosciences-changchun-genescience-pharma-regeneron_696241.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-696241","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/696241","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=696241"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/696241\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=696241"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=696241"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=696241"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}